HESI Assembly Agenda

10 June 2014
11:00 a.m. - 12:00 p.m. Eastern

Washington Ballroom
Westin Georgetown Hotel
Washington, DC 20037

Session Leader: Laurie Hanson, DVM, PhD, Pfizer, HESI President

11:00 am Welcome
11:05 am Official Representative Training Session
11:35 am HESI Business Updates
11:45 am Official Representatives Vote for Trustees and EIC Science Advisors
11:50 am Open Discussion
12:00 pm Adjourn
HESI BUSINESS MEETING, ELECTION OF TRUSTEES, EIC SCIENCE ADVISORS, AND OFFICIAL REPRESENTATIVES TRAINING/DISCUSSION SESSION

Tuesday, 10 June, 2014
11:00 a.m. - 12:00 p.m.

Washington Ballroom
Westin Georgetown Hotel
Washington, DC 20037

ANTICIPATED ATTENDEES

Prof. Herman Autrup  University of Aarhus
Dr. Sonja Beken  Federal Agency Medicines and Health Products
Ms. Beth-Ellen Berry  ILSI
Prof. Alan Boobis  Imperial College London
Dr. David Brewster  Vertex Pharmaceuticals
Mr. Kyle Brunette  HESI
Dr. Stuart Cagen  Shell Health
Dr. Connie Chen  ILSI Health and Environmental Sciences Institute
Dr. Samuel Cohen  University of Nebraska Medical Center
Dr. Myrtle Davis  National Cancer Institute, NIH
Mr. Yoshihito Deguchi  Sumitomo Chemical America
Dr. Dennis Devlin  Exxon Mobil Corporation
Ms. Nancy Doerrer  ILSI Health and Environmental Sciences Institute
Dr. Yvonne Dragan  DuPont
Dr. David Eaton  University of Washington
Dr. Michal Eldan  Luxembourg Industries Ltd.
Dr. Michelle Embry  HESI
Ms. Brianna Farr  ILSI Health and Environmental Sciences Institute
Dr. Timothy Gant  Centre for Radiation, Chemical and Environmental Hazards
Dr. Andrew Glickman  Chevron Corporation
Dr. Daniel Goldstein  Monsanto
Dr. Jay Goodman  Michigan State University
Dr. Eva Guinan  Harvard Medical School
Dr. Patrick Guiney  S.C. Johnson & Son, Inc.
Dr. Peggy Guzzi-Brick  Janssen Pharma R&D, LLC
Dr. Laurie Hanson  Pfizer Inc.
Dr. Suzie Harris  ILSI/ILSI Research Foundation
Dr. Michael Holsapple  Covance
Dr. Jerry Hjelle  Monsanto Company
Dr. Julia Hui  Celgene Corporation
Mr. Alex Keller  HESI
Dr. Douglas Keller  Sanofi
Prof. James Klaunig  Indiana University
Dr. Serrine Lau  University of Arizona
Dr. Jose Manautou  
University of Connecticut

Dr. Charlene McQueen  
US Environmental Protection Agency

Prof. Angelo Moretto  
University of Milano, Italy

Prof. Lee Nadler  
Harvard University

Dr. Stephen Newsholme  
GlaxoSmithKline

Dr. Raegan O’Lone  
HESI

Dr. Timothy Pastoor  
Syngenta

Ms. Syril Pettit  
HESI

Ms. Jennifer Pierson  
HESI

Dr. Robert Rickard  
DuPont

Prof. Ruth Roberts  
AstraZeneca

Dr. Denise Robinson Gravatt  
Pfizer Inc.

Dr. Craig Rowlands  
The Dow Chemical Company

Dr. R. Dustan Sarazan  
Data Sciences International

Mr. Shawn Sullivan, Esq.  
ILSI

Ms. Ayako Takei  
ICaRuS Japan Limited

Dr. Jennifer Tanir  
HESI

Dr. Martin van den Berg  
Utrecht University

Dr. Jan Willem Van der Laan  
Medicines Evaluation Board

Mr. Tetsuro Wakatsuki  
invivosciences inc.

Prof. Kendall Wallace  
University of Minnesota Medical School - Duluth campus

Dr. Harold Zenick  
US Environmental Protection Agency
New Nominees
Keiichiro Sato, PhD, Director, Drug Safety Research Laboratories, Takeda Pharmaceutical Company Limited
Myrtle Davis, DVM, PhD, Chief, Toxicology and Pharmacology Branch Developmental Therapeutics Program Division of Cancer Treatment and Diagnosis, The National Cancer Institute
Sonja Beken, PhD, Coordinator Non-Clinical Assessors, Coordinator Oncology Division Evaluators, DG PRE Authorisation, Belgium
David Brewster, PhD, DABT, VP and Global Head Drug Safety Evaluation, Global Exploratory Development, Vertex Pharmaceuticals
David L. Eaton, PhD, Dean and Vice Provost, The Graduate School, University of Washington
Stefan Platz, PhD, Global Head of Drug Safety and Metabolism, AstraZeneca.

Re-Nominees
Scott E. Belanger, PhD, Procter & Gamble Company
Ernie Harpur, BSc, PhD, ATS, FBTS, Newcastle University
Serrine S. Lau, PhD, University of Arizona
Charlene A. McQueen, PhD, ATS, US Environmental Protection Agency
Angelo Moretto, MD, PhD, University of Milan
Timothy P. Pastoor, PhD, DABT, Syngenta Crop Protection, Inc.
Kendall B. Wallace, PhD, University of Minnesota Medical School

2013-2014 Board of Trustees
Cynthia A. Afshari, PhD, DABT, Amgen, Inc.
Herman N. Autrup, PhD, University of Aarhus
Scott E. Belanger, PhD, The Procter & Gamble Company
Brian R. Berridge, DVM, PhD, DACVP, GlaxoSmithKline
Alan R. Boobis, OBE, PhD, Imperial College London
Samuel M. Cohen, MD, PhD, University of Nebraska Medical Center
Dennis J. Devlin, PhD, Exxon Mobil Corporation
Shoji Fukushima, MD, PhD, Japan Bioassay Research Center
Jay I. Goodman, PhD, Michigan State University
Patrick D. Guiney, PhD, S.C. Johnson & Son, Inc.
Peggy J. Guzzie-Peck, MS, PhD, DABT, Janssen Pharma R&D, LLC
Laurie A. Hanson, DVM, PhD, DABT, Pfizer Inc.
Ernie Harpur, BSc, PhD, ATS, FBTS, Newcastle University
Serrine S. Lau, PhD, University of Arizona
Lois Lehman-McKeeman, PhD, Bristol-Myers Squibb Company
Charlene A. McQueen, PhD, ATS, Research Triangle Park, NC
Angelo Moretto, MD, PhD, University of Milan
Timothy P. Pastoor, PhD, DABT, Syngenta Crop Protection, Inc.
Martin A. Philibert, PhD, University of Michigan
Robert W. Rickard, PhD, DuPont
J. Craig Rowlands, PhD, DABT, The Dow Chemical Company
Atsushi Sambuissho, DVM, PhD, Daiichi Sankyo Co., Ltd.
Lewis L. Smith, BSc, PhD, FRCPath, University of Leicester
James L. Stevens, PhD, Eli Lilly and Company
Hiroyuki Tsuda, MD, PhD, Nagoya City University
Martin van den Berg, PhD, Utrecht University
Jan Willem van der Laan, PhD, Medicines Evaluation Board
Bennard van Ravenzwaay, Dr. rer. nat., BASF SE
2014-2015 Proposed Board of Trustees
Herman N. Autrup, PhD, University of Aarhus
Sonja Beken, PhD, Federal Agency Medicines and Health Products
Scott E. Belanger, PhD, Procter & Gamble Company
Brian R. Berridge, DVM, PhD, DACVP, GlaxoSmithKline
Alan R. Boobis, OBE, PhD, Imperial College London
David Brewster, PhD, DABT, Vertex Pharmaceuticals Incorporated
Samuel M. Cohen, MD, PhD, University of Nebraska Medical Center
Myrtle Davis, DVM, PhD, The National Cancer Institute
Dennis J. Devlin, PhD, Exxon Mobil Corporation
David L. Eaton, PhD, University of Washington
Shoji Fukushima, MD, PhD, Japan Bioassay Research Center
Patrick D. Guiney, PhD, S.C. Johnson & Son, Inc.
Peggy J. Guzzie-Peck, MS, PhD, DABT, Janssen Pharma R&D, LLC
Laurie A. Hanson, DVM, PhD, DABT, Pfizer Inc.
Ernie Harpur, BSc, PhD, ATS, FBTS, Newcastle University
Serrine S. Lau, PhD, University of Arizona
Lois Lehman-McKeeman, PhD, Bristol-Myers Squibb Company
Charlene A. McQueen, PhD, ATS, Research Triangle Park, NC
Angelo Moretto, MD, PhD, University of Milan
Timothy P. Pastoor, PhD, DABT, Syngenta Crop Protection, Inc.
Martin A. Philbert, PhD, University of Michigan
Stefan J. Platz, PhD, AstraZeneca Pharmaceuticals LP
J. Craig Rowlands, PhD, DABT, The Dow Chemical Company
Atsushi Sambuissho, DVM, PhD, Daiichi Sankyo Co., Ltd.
Keiichiro Sato, PhD, Takeda Pharmaceutical Company Limited
Lewis L. Smith, BSc, PhD, FRCPath, University of Leicester
James L. Stevens, PhD, Eli Lilly and Company
Martin van den Berg, PhD, Utrecht University
Jan Willem van der Laan, PhD, Medicines Evaluation Board
Bennard van Ravenzwaay, Dr. rer. nat., BASF SE
Kendall B. Wallace, PhD, University of Minnesota
Belanger, Scott E., PhD

Scott Belanger is presently a Research Fellow in Procter & Gamble’s corporate Global Product Stewardship safety organization where he has broad leadership responsibilities for environmental toxicology, science, and technology guidance from an environmental perspective. He holds degrees from the University of Wisconsin (B.S.), Bowling Green State University (M.S.) and Virginia Tech (Ph.D. and post-doctoral appointment). Prior to joining P&G in 1989, he was an Assistant Professor in Environmental Toxicology at the University of Louisiana-Lafayette. During his tenure at P&G Scott directed research at P&G’s Experimental Stream Facility in southwestern Ohio evaluating the ecological impacts of P&G’s highest volume detergent chemicals. Later he assumed responsibility for P&G’s global environmental toxicology function including guidance for upstream technology development on environmental matters. Scott is a recognized authority in the responses of aquatic life to man-made and natural stressors and has authored over 100 published scientific articles, books and book chapters on these topics. He has served on numerous national and international panels providing advice to organizations such as the U.S. Environmental Protection Agency, the OECD (Organization for Economic Co-operation and Development, an international governing body), the European Commission, the Japanese Ministry of Environment, Trade and Industry, and Environment Canada. Presently in P&G’s Corporate Environmental Stewardship Organization he directs research on ecological and toxicological responses of fish, invertebrates and algae to consumer product chemicals and advises P&G broadly on the development of new technologies and issues relating to sustainable development.

Boobis, Alan R., OBE, PhD

Dr. Alan Boobis is professor of biochemical pharmacology in the Department of Medicine, Imperial College London and Director of the Public Health England Toxicology Unit. He has been a member of Imperial College London (initially at the Royal Postgraduate Medical School, which merged with the College in 1997) for over 35 years. His main research interests lie in mechanistic toxicology, drug metabolism, toxicity pathway analysis and increasingly over the last 20 years or so, in the application of knowledge in these areas to risk assessment. He has published over 220 original research papers (H-factor ~60) and until recently was an Editor-in-Chief of Food and Chemical Toxicology. He is a member of a number of international advisory committees, including co-chair of the WHO Mode of Action Steering group, JECFA (veterinary residues - chair) and JMPR (alternating chair). He was a member (1993-9) and deputy chair (1999-2002) of the UK Advisory Committee on Pesticides. He was a member (2003-9) and deputy chair (2009-12) of the UK Committee on Toxicity, a member of the UK Committee on Carcinogenicity (2003-20012), the EFSA Panel on Contaminants in the Food Chain (2009-2012) and a member (2003-6) and deputy chair (2006-9) of the EFSA Panel on Plant Protection Products. He is a member and a past chairman of the Board of Trustees of ILSI HESI and is vice president of ILSI Europe. He is also currently a member of the Board of Trustees of ILSI. He is involved in several HESI, ILSI RF and ILSI Europe projects. He is a fellow of the Society of Biology and of the British Toxicology Society. He has served as president of Eurotox and received the Merit Award in 2009. He is a past chair of the British Toxicology Society and received the John Barnes Prize Lectureship in 2013. He received an OBE in 2003 for his work on the risk assessment of pesticides. Alan also received the Royal Society of Chemistry’s Toxicology Award at the 2014 Society of Toxicology Annual Meeting.

Beken, Sonja, PhD

Sonja Beken obtained her Master in Biological Sciences at the Vrije Universiteit Brusel (VUB), Belgium, holds a PhD in Pharmaceutical Sciences (VUB) and finalised a Master in Applied Toxicology at the University of Surrey, UK. From 1998 until 2000 she worked as Scientific Staff Member at Belgian Platform for Alternative Methods (BPAM). From 2003 to 2009 she acted as member of ECVAM’s scientific advisory committee (ESAC). Today, Sonja Beken is the coordinator of the Unit of non-clinical evaluators within the Belgian Federal
Agency for Medicines and Health Products (FAMHP). This Unit is responsible for the evaluation of non-clinical data (pharmacology, pharmacokinetics and toxicology) submitted to support all phases of the life cycle of drug development (e.g. marketing authorization applications, clinical trial applications, EU and national scientific advice, paediatric investigation plans, etc). She is a Member of the Safety Working Party (SWP) of the European Committee on Human Medicinal Products (CHMP) at the European Medicines Agency (EMA). Since June 2011, Sonja Beken is the Chair of the CVMP/CHMP Joint Ad Hoc Expert Group on 3R’s (JEG 3Rs) at the EMA. Her main areas of expertise relate to regulatory science, (in vitro) toxicology and metabolism as well as alternative models to animal experiments.

**Brewster, David, PhD, DABT**

Dr. Brewster is a Board certified toxicologist with >30 years of research experience in toxicology and nearly 20 years experience in the pharmaceutical industry. He has extensive experience in the development of new molecular entities (both small and large molecules), medical devices, reformulations of marketed products and global product registration and support. At Monsanto he developed and led the thyroid biochemical toxicology and cell proliferation programs. During his tenure at Aventis and its predecessor companies he built and staffed an investigative toxicology group and assumed increasing responsibilities up to the Director of Toxicology and Head of US projects. At Purdue he reorganized and re-energized the organization and integrated the toxicology, pathology, bioanalytical, drug metabolism and toxicokinetic groups into a high performing team. At Roche he was Vice-President NonClinical Drug Safety responsible for preclinical safety assessment and NCS Site Head in Nutley, NJ with oversight of the toxicology, pathology, drug metabolism, bioanalytics, and pharmacokinetics/toxicokinetics groups and responsible for setting policy and directing strategic planning for non-clinical safety testing. Currently at Vertex as VP and Head Global Drug Safety Evaluation he is responsible for Global strategic preclinical regulatory strategies, providing scientific advice and oversight for early and late stage drug development projects. In addition his responsibilities include establishment of Scientific and Educational programs, building the presence and recognition of Vertex to academia, US trade organizations, and professional drug development organizations and represents the company externally on various Scientific and Pharma trade organizations. His interests not only include drug development and working collaboratively with the FDA but also seeking alternatives to classical toxicity testing, evaluating the application of stem cell technologies and investigating the use non-invasive biosensors and whole body imaging in safety assessment.

**Davis, Myrtle A., PhD**

Dr. Davis earned a PhD in Toxicology from the University of Illinois Champaign-Urbana and completed a postdoctoral fellowship in Toxicologic Pathology at the University of Maryland, School of Medicine. She completed Undergraduate work in Chemistry and obtained her Doctor of Veterinary Medicine degree from Tuskegee University, School of Veterinary Medicine. Dr. Davis is the currently the Branch Chief for Toxicology and Pharmacology in the Division of Cancer Diagnostics and Treatment of the National Cancer Institute (NCI). Dr. Davis moved to the NCI from Lilly Research Labs, Eli Lilly and company where she held the position of Research Advisor in the Investigative Toxicology Group. Prior to taking the position at Eli Lilly, Dr. Davis was an Associate Professor in the Department of Pathology at the University of Maryland, School of Medicine where she had an active research program exploring mechanisms of toxicant-induced apoptosis and the role of protein phosphorylation.

**Eaton, David L., PhD**

Dr. Eaton received his Ph.D. in pharmacology from the University of Kansas Medical Center (KUMC) in 1978. He joined the UW faculty as an Assistant Professor of Environmental Studies and Environmental Health in 1979. He is now Professor of Environmental and Occupational Health Sciences, and also holds adjunct appointments in Public Health Genetics and Medicinal Chemistry. He served as Associate Dean for Research in the School of Public Health from 2000-2005. He is currently founding Director of the Center for Ecogenetics and Environmental Health at the University of Washington, and also serves as Associate Vice Provost for Research for the UW. Nationally, he has served as President of the Society of Toxicology and Treasurer of the American Board of Toxicology, and on numerous other Boards and Commissions, including the NAS/NRC Board of Environmental Studies and Toxicology; he has chaired or served on numerous National Academy committees dealing with controversial areas in toxicology, such as 'safe' levels of arsenic in drinking water, evaluation of the EPA's Risk Assessment on Dioxins in the environment, and a review of
the federal strategy to address environmental health and safety issues related to
nanomaterials. He has published over 150 scientific articles and book chapters
in the field of toxicology, and is author of several key textbook chapters on the
principles of toxicology, such as ‘Casarett and Doull's Toxicology’,
'Comprehensive Toxicology' and 'Textbook of Clinical Occupational and
Environmental Medicine'. Dr. Eaton is an Elected Fellow of the American
Association for the Advancement of Science and the Academy of Toxicological
Sciences, and is a Lifetime National Associate of the National Academies of
Sciences.

Harpur, Ernie, BSc, PhD, ATS, FBTS

Following periods of doctoral and post-doctoral research in toxicology, Ernie
spent 13 years in academia where his research interests centered on
investigations of mechanisms of toxicity. Ernie subsequently worked for 21
years in Drug Safety Assessment in the pharmaceutical industry based in
Europe and the USA, for the last 9 years as Global Head of Scientific Affairs and
Regulatory Standards. Since leaving industry in 2010, Ernie has held an
honorary position in Toxicology within the Institute of Cellular Medicine at
Newcastle University and engaged in various scientific advisory roles. He is a
Registered Toxicologist and is active in several professional societies (past
Scientific Secretary of the British Toxicology Society (BTS) and past President of
EUROTOX). He is a Fellow of the British Toxicology Society, a Fellow of the
Academy of Toxicological Sciences and an honorary member of EUROTOX. He
has served on several expert committees, including the Safety, Efficacy and
Adverse Reactions Sub-Committee of the UK Committee on Safety of
Medicines. He has been active in a number of scientific consortia on both sides
of the Atlantic serving recently as Chair of the HESI Renal Biomarkers
Committee (now Scientific Advisor to this committee) and Vice Chair of the HESI
Emerging Issues Committee and as a member of the Advisory Committee of the
Predictive Safety Testing Consortium of the Critical Path Institute. Currently he is
a member of the Board of Trustees, Executive Committee and Program Strategy
and Stewardship Committee of HESI and chair of the Scientific Advisory Board
of the UK public private partnership, Stem Cells for Safer Medicines. He is a
member of the Executive Committee of the British Toxicology Society (recently
elected Vice President). He has published more than 90 journal articles, reviews
and book chapters and is a member of the editorial board of Toxicology Letters
and Human & Experimental Toxicology.

Lau, Serrine S., PhD

Serrine S. Lau received her Ph.D. in Pharmacology from the University of
Michigan. She was a Postdoctoral Fellow and Senior Staff Fellow with Dr. James
Gillette and Dr. Michael Boyd at NHLBI and NCI, NIH, respectively. Dr. Lau is a
Professor of Pharmacology and Toxicology, Director of the Southwest
Environmental Health Sciences Center (http://swehsc.pharmacy.arizona.edu/)
and Director of the Arizona Board of Reagents Center for Toxicology in the
College of Pharmacy at the University of Arizona. Prior to her current position,
Dr. Lau spent 17 years in the Division of Pharmacology and Toxicology at the
University of Texas at Austin, and served as the Director of the NIEHS-
supported Toxicology Training Program. Dr. Lau's research focuses on three
areas; (i) mechanisms of chemical-induced nephrotoxicity and
nephrocarcinogenicity (ii) prostanoid and retinoid-mediated cytoprotection
against ROS induced tissue injury, and (iii) proteomics approaches for the
identification of chemical-induced protein post-translational modifications, and
biomarker discovery for diseases including diabetes, asthma and cancer. Dr.
Lau collaborates extensively with basic and clinical scientists, integrating the
basic sciences with translational opportunities in environmental health sciences
research. Dr. Lau has over 150 publications and 300 published abstracts. Dr.
Lau's research work has been funded by grants from the National Institutes of
Health, National Science Foundation, the American Association of Colleges of
Pharmacy, and the Pharmaceutical Manufacturers Association Foundation. Dr.
Lau plays an active role in a number of professional organizations serving the
field of toxicology and the environmental health sciences. She has served on
many elected and appointed committees at SOT, ASPET, ISSX, NIH Study
Section grant review panels and National Academy of Sciences. She completed
her appointment as a member of the HESI Emerging Issues Steering Committee
(June 2011), Chair of SOT Awards Committee (May 2012) and Chair of the SOT
Board of Publications (May 2013). She is currently a member of the HESI Board
of Trustees, HESI Treasurer and a member of the NIEHS Board of Scientific
Counselors.
McQueen, Charlene A., PhD, ATS
Charlene A. McQueen assumed the position of Director of the Integrated Systems Toxicology Division in the US EPA National Health and Environmental Effects Research Laboratory in January 2011. Prior to that, she held positions at the Harrison School of Pharmacy, Auburn University (2007-2011) and the Department of Pharmacology and Toxicology at the University of Arizona (1990-2007). Dr. McQueen received a B.S. in Biology from Marywood College, Scranton, PA, M.S. in Pharmacology from New York University and Ph.D. in Human Genetics from the University of Michigan. Her research is in the areas of pharmacogenomics, toxicogenomics and chemical carcinogenesis. She is the Editor-in-Chief of the second edition of Comprehensive Toxicology and a member of the editorial board for References Modules in Biomedical Sciences. Dr. McQueen is an American Association for the Advancement of Science Fellow and a Fellow in the Academy of Toxicological Sciences (ATS). She was a member of the Board of Directors of ATS (2004-2009) serving as President in 2007-2008. Dr. McQueen received the Society of Toxicology (SOT) Public Communications Award (2003) and the SOT AstraZeneca Traveling Lectureship Award (2004). She has served on the SOT Program Committee, Education Committee, and chaired the K-12 Education Subcommittee. She has been a member of the SOT Council (1999-2001), the Council of the International Society for the Study of Xenobiotics (ISSX) (1994-1997) and the Executive Committee of the Drug Metabolism Division of the American Society of Pharmacology and Experimental Therapeutics (1997-2000). Dr. McQueen was on the Environmental Health Sciences Committee of the National Institute of Environmental Health Sciences, the Board of Scientific Councilors of the National Toxicology Program and the National Institutes of Health Cancer Etiology Study Section. Currently, Dr. McQueen is a member of the HESI Board of Trustees, the Board Secretary and a member of the ISSX Committee on Regulatory Affairs.

Moretto, Angelo , MD, PhD
Angelo Moretto is a professor of Occupational Medicine and Toxicology in the Department of Biomedical and Clinical Sciences at the University of Milan (Milan, Italy). Since 2006, he is also Director of the International Center for Pesticides and Health Risks Prevention (ICPS) at “Luigi Sacco” Hospital (Milan, Italy). He has been and currently is a member of many international and national committees for the risk assessment of exposure to chemical substances, in particular pesticides, and for the improvement, harmonization and innovation of risk assessment methods. Currently, he is a member of the following scientific organizations: Academy of Toxicological Sciences, International Commission on Occupational Health, International Neurotoxicology Association (Board member 2007-2009), Società Italiana di Medicina del Lavoro e Igiene Industriale (Board Member since 2011), Società Italiana di Tossicologia, and the Society of Toxicology. Prof. Moretto is a reviewer for over 15 journals, and has authored more than 70 papers in peer-review journal on toxicology, mainly neurotoxicology of pesticides, occupational toxicology, and toxicological risk assessment, and more than 20 review papers and book chapters.

Pastoor, Timothy P., PhD, DABT
Dr. Pastoor obtained his PhD in toxicology from the University of Michigan, is certified by the American Board of Toxicology (DABT), and is a long-standing, active member of the Society of Toxicology. Dr. Pastoor has over 30 years of international experience in fundamental toxicity testing, mode of action research, and human health risk assessment. For the majority of his career, including positions with DuPont, ICI, Zeneca, Novartis, and Syngenta, Dr. Pastoor led toxicology and risk assessment experts in the conduct of safety, health, and environmental studies to assess risk to humans and the environment. In his current role as Principal Scientist for Syngenta, Dr. Pastoor oversees toxicological research projects and product development and is a frequent lecturer on toxicology and risk assessment subjects. Dr. Pastoor has been involved in numerous ILSI-HESI projects. He helped organize the first peroxisome proliferation workshop, was a co-author of the Human Relevancy Framework, and co-chair of the Agricultural Chemical Safety Assessment committee. He is currently co-chairing the RISK21 project and is HESI’s vice-president.

Platz, Stefan J. DVM, PhD, DABT
Stefan joined AstraZeneca in February 2012 and is the Global Head Drug Safety and Metabolism in IMED. In this function he is responsible for Toxicology, Pathology, DMPK and Laboratory Animal Sciences. Stefan represents DSM at the ESPC and IMLT. Prior to joining AZ, Stefan was with Hoffmann-La Roche in
Basel and before in Palo Alto, leading the non-clinical safety organisations at these sites and in addition had extended periods of responsibilities for the early safety as well as biologics safety strategy. He started his career in 1996 at Boehringer Ingelheim as a pathologist with short term secondments at the Ohio State University and as a fellow of the Pembroke college in Cambridge. In 2001 he contributed to the successful filing to Tenecteplase, a tissue plasminogen activator together with the preclinical expert at Genentech. Stefan received his veterinary degree from the University of Munich, is a German certified veterinary pathologist and a Diplomate of the American Board of Toxicology. His is particularly interested in exploring novel approaches and technologies to improve the understanding of human safety risks prior to testing in clinical trials. In his spare time he likes doing outdoor activities with his family.

Sato, Keiichiro, DVM, PhD, DJSOT, DABT
Dr. Keiichiro Sato is Director, Drug Safety Research Laboratories, at Takeda Pharmaceutical Company Limited in Kanagawa, Japan. He oversees a staff of approximately 100 people who conduct non-clinical safety and toxicity studies on candidates for clinical development, new drug applications (NDA), and post-marketing non-clinical research. Dr. Sato has been with Takeda since 1988. He earned his DVM from the Ministry of Agriculture, Forestry and Fisheries (Tokyo) in 1988, and his PhD in Veterinary Medicine from the University of Tokyo in 1997. He is a Diplomate of the Japanese Society of Toxicology (JST) and the American Board of Toxicology. Dr. Sato has served in several JST leadership roles over the last decade, including his current role as a JST Councilor. Since 1996, he has served as Councilor of the Japanese Society of Veterinary Cardiology. Dr. Sato is the author of numerous publications and a frequent presenter at technical meetings throughout Japan, Europe, and the United States.

Wallace, Kendall B., PhD
Kendall B. Wallace is a Professor and Associate Dean at the University of Minnesota Medical School on the Duluth campus. Dr. Wallace received his B.S. in Biochemistry from Michigan State University in 1975 and his Ph.D. in Physiology in 1979 from the same institution. He completed a two-year postdoctoral fellowship in the Toxicology Center at the University of Iowa before accepting an academic appointment first in Pharmacology and then Biochemistry and Molecular Biology at the University of Minnesota, Duluth. He has received a number of academic awards and recognitions, including “Basic Science Teacher of the Year” on 4 separate occasions. Dr. Wallace’s research interest is on the mitochondrion as a target for chemical-induced toxicity and the biochemical and molecular mechanisms that mediate such metabolic diseases. Dr. Wallace is a Diplomate of the American Board of Toxicology and served President of its Board of Directors in 2001-02. He is also Past-President of the Society of Toxicology and a Fellow of the Academy of Toxicological Sciences and president of its governing council. He has served on the executive committees for the Toxicology Division of ASPET (1992-98) and the IUTOX International Congress of Toxicology (1993-95; 2013-current). Dr. Wallace is co-Editor of the journal Toxicology and has served on scientific advisory panels to the NIEHS, NHLBI, the U.S. EPA and the U.S. FDA, including the Food Safety Advisory Committee. He is also a member of the Medical Expert Panel for the Vaccine Injury Compensation Program of the HHS. Dr. Wallace is a veteran with the ILSI organization as he has served as a scientific advisor to both the Risk Science Institute (1997-98) and the Health and Environmental Sciences Institute (1998-current).
Afshari, Cynthia A., PhD. DABT

Cynthia A. Afshari is a Scientific Executive Director at Amgen, Inc. Her expertise is in the areas of molecular toxicology and drug development of small and large molecules. At Amgen, she heads the Discovery Toxicology Dept. where her primary role is to manage the preclinical safety aspects of the early portfolio by optimizing strategies for screening and selecting targets and drug candidates. In addition, she has responsibility for a number of investigative and predictive safety laboratory based teams in the areas of molecular toxicology, in vitro assays, biochemical toxicology, genetic toxicology and target organ based toxicology. Her group also conducts research through external collaborations. Prior to joining Amgen, Dr. Afshari was a Senior Staff Scientist at the National Institute of Environmental Health Sciences where she led a research program within the Laboratory of Molecular Carcinogenesis and founded the NIEHS microarray center. Dr. Afshari has served on study sections for both NIEHS and NCI in the area of emerging technologies and risk assessment. She has also served as Chair of the HESI committee on Genomics and also on a National Academy of Sciences committee covering genomics applications in predictive toxicology. She recently finished her tenure as Chair of the Scientific Advisory Board for the National Center for Toxicological Research at FDA. Dr. Afshari currently serves on the editorial boards for Toxicological Sciences, Environmental Health Perspectives, and Chemical Research in Toxicology. She is an active member of the Society of Toxicology and has served on the executive committee for several specialty committees. She earned her Ph.D. in Toxicology from the University of North Carolina, Chapel Hill, and is a board-certified toxicologist.

Autrup, Herman Nybro PhD

Prof. Herman Autrup is past-President, EUROTOX, president, IUTOX, and holds positions as Professor of Environmental Medicine at the University of Aarhus in Århus, Denmark, and Adjunct Professor at the Chulabhorn Graduate Institute in Bangkok, Thailand. He received his Ph.D. in Experimental Pathology from the University of Nairobi in 1995 and a Candidatus Scientiarum in Organic Chemistry from the University of Copenhagen in 1971. He is member of the Danish Academy of Technical Sciences and a fellow of ATS. His research interest is molecular epidemiology, with focus on molecular markers of susceptibility and exposure, air pollution. He is currently coordinating an interdisciplinary project on the safety of nanoparticles. Prof. Autrup is a member of several editorial boards including Tox Sci, and is invited reviewer for 15 different journals in the area of environmental toxicology and nanotoxicology, and is often invited to give lectures at international meetings and international research institutes. He has authored more than 200 publications in peer-reviewed journals and more than 50 publications in books and meeting proceedings and is the co-editor of 6 books. He received the European Environmental Mutagen Society’ Fritz Sobel award in 2006 for his contribution in the area of carcinogen-DNA adducts, the Princess Chulabhorn of Thailand’s Gold Medal Award in 2007, Eurotox Merit award in 2013 and the SOT Educational award in 2014. He is a member of the Society of Toxicology (USA), and the European Society of Toxicology (honorary member).

Belanger, Scott E., PhD

Scott Belanger is presently a Research Fellow in Procter & Gamble’s corporate Global Product Stewardship safety organization where he has broad leadership responsibilities for environmental toxicology, science, and technology guidance from an environmental perspective. He holds degrees from the University of Wisconsin (B.S.), Bowling Green State University (M.S.) and Virginia Tech (Ph.D. and post-doctoral appointment). Prior to joining P&G in 1989, he was an Assistant Professor in Environmental Toxicology at the University of Louisiana-Lafayette. During his tenure at P&G Scott directed research at P&G’s Experimental Stream Facility in southwestern Ohio evaluating the ecological impacts of P&G’s highest volume detergent chemicals. Later he assumed responsibility for P&G’s global environmental toxicology function including guidance for upstream technology development on environmental matters. Scott is a recognized authority in the responses of aquatic life to man-made and natural stressors and has authored over 100 published scientific articles, books and book chapters on these topics. He has served on numerous national and international panels providing advice to organizations such as the U.S. Environmental Protection Agency, the OECD (Organization for Economic Co-operation and Development, an international
Brian Berridge is Director and Head of WW Animal Research Strategy in the Office of Animal Welfare, Ethics and Strategy at GlaxoSmithKline. In that position he leads efforts to advance the scientific impact of animal and non-animal modeling in support of pharmaceutical development. He has held previous positions as a Director of Regulatory & Discovery Pathology at GSK and Principal Research Pathologist at Eli Lilly & Company. Brian is an Oklahoma State University-trained veterinarian with residency and PhD training from Texas A&M University. He is a Diplomate of the American College of Veterinary Pathologists and holds an adjunct Associate Professor position in the Department of Population Health and Pathobiology at North Carolina State University. He additionally teaches cardiovascular toxicology at the University of North Carolina. He is a member of the Executive Board and Board of Trustees for the ILSI Health and Environmental Sciences Institute where he also co-chairs the HESI Cardiac Safety Technical Committee, the Integrated CV Strategies Working Group, and the Translational Preclinical Imaging Technical Committee. Brian also chairs an international effort to harmonize cardiovascular nomenclature in regulatory toxicologic pathology and a CV Specialty Interest Group within the Society of Toxicologic Pathologists.

Alan Boobis is professor of biochemical pharmacology in the Department of Medicine, Imperial College London and Director of the Public Health England Toxicology Unit. He has been a member of Imperial College London (initially at the Royal Postgraduate Medical School, which merged with the College in 1997) for almost 40 years. His main research interests lie in mechanistic toxicology, drug metabolism, toxicity pathway analysis and increasingly over the last 20 years or so, in the application of knowledge in these areas to risk assessment. He has published around 230 original research papers (H-factor ~60) and for several years served as an Editor-in-Chief of Food and Chemical Toxicology. He is a member of a number of international advisory committees, including co-chair of the WHO Mode of Action Steering group, JECFA (veterinary residues - chair) and JMPR (alternating chair). He was a member (1993-9) and deputy chair (1999-2002) of the UK Advisory Committee on Pesticides. He was a member (2003-9) and deputy chair (2009-12) of the UK Committee on Toxicity, a member of the UK Committee on Carcinogenicity (2003-2013), the EFSA Panel on Contaminants in the Food Chain (2009-2012) and a member (2003-6) and deputy chair (2006-9) of the EFSA Panel on Plant Protection Products. He is a member and a past chairman of the Board of Trustees of ILSI HESI, vice-president of ILSI Europe and vice-chair of ILSI. He is involved in several HESI, ILSI RF and ILSI Europe projects. He is a fellow of the Society of Biology and of the British Toxicology Society. He has served as president of Eurotox and received the Merit Award in 2009. He is a past chair of the British Toxicology Society and received the John Barnes Prize Lectureship in 2013. He was recipient of the Royal Society of Chemistry Toxicology Award in 2013. He received an OBE in 2003 for his work on the risk assessment of pesticides. Alan also received the Royal Society of Chemistry’s Toxicology Award at the 2014 Society of Toxicology Annual Meeting.

Dr. Samuel M. Cohen (MD, PhD, University of Wisconsin – Madison, 1972) completed a residency in anatomic and clinical pathology at St. Vincent Hospital, Worcester, Massachusetts, in 1975, and became board certified in pathology the following year. He was a visiting professor in the department of Dr. Nobuyuki Ito at Nagoya City University Medical School, Nagoya, Japan, (1976 to 1977) a staff pathologist at St. Vincent Hospital (1975 to 1981), and associate professor of pathology at the University of Massachusetts Medical School (1977 to 1981). In 1981, he became Professor and Vice Chairman of Pathology in the College of Medicine and Professor at the Eppley Institute, University of Nebraska Medical Center. In 1992, he was named Chairman of the Department of Pathology and Microbiology at Nebraska, continuing in that position until 2007. Dr. Cohen’s research has focused on mechanisms of carcinogenesis, with a focus on the role of cell proliferation in the carcinogenic process, primarily utilizing the urinary bladder as a model system. Most recently this has involved investigations into the mechanisms of bladder carcinogenesis produced by arsenicals and PPAR agonists. Research with PPAR agonists has led to investigations into mechanisms of induction of hemangiosarcomas. In addition, his research has involved clinical investigations of various aspects of urologic pathology and extrapolation between animals and humans. This research has resulted in more than 350 publications. He has been a member of...
Devlin, Dennis J., PhD

Dennis joined Exxon Biomedical Sciences in 1987. His early work focused on site remediations and product risk assessments. He transferred to the Brussels headquarters of Exxon Chemical International, Inc. in 1991 where he directed the toxicology program for European Exxon business groups and area offices. Following the merger of Exxon and Mobil, he became Director of Toxicology and Environmental Sciences, providing global affiliates and support organizations with consulting services, science development, and technical support. In 2009, he assumed the role of Sr. Environmental Health Advisor for Exxon Mobil Corporation where he provides strategic guidance for environmental health policy and planning. Dennis is a Board Trustee of the International Life Sciences Institute (ILSI) and past president of the ILSI Health and Environmental Sciences Institute, Chairman of the Petroleum Industry High Production Volume Testing Committee, Chairman of the American Petroleum Institute’s Exploration and Production Health Issues Group, and a member of the Institute of Medicine of the National Academies Roundtable on Environmental Health Sciences, Research, and Medicine. Dennis received a Ph.D. in Toxicology from Dartmouth College.

Fukushima, Shoji, MD, PhD

Dr. Shoji Fukushima graduated from medical school in 1967, received his MD in 1968, and his PhD in 1973 under the supervision of Prof. Hisamasa Sato, all from Nagoya City University Medical School, Japan. He became a faculty member at Nagoya City University in 1968, and was associate research fellow in the Department of Pathology, University of Massachusetts Medical School, 1977-79. In 1979, Dr. Fukushima returned to the First Department of Pathology, Nagoya City University Medical School as assistant professor (Chairman, Prof. Nobuyuki Ito), and in 1980 was promoted to associate professor. In 1990, he became Professor and Chairman of the First Department of Pathology, Osaka City University Medical School. In 2006, he retired from Osaka City University and became Director of the Japan Bioassay Research Center, Japan Industrial Safety and Health Association. He has made significant contributions as a member of numerous scientific organizations and as a member of several editorial boards, including Cancer Letters, Pathology International, Cancer Science, Japanese Journal of Clinical Oncology and Asian Pacific Journal of Cancer Prevention. He has served on numerous Japanese governmental committees, including the Food Additive Expert Commission (Former Chairman), the Food Safety Committee of the Cabinet Office, Chairman of the Commission for grants of food safety research from the Ministry of Health, Labor and Welfare, and a member of the Chemical Council of the Ministry of Economy, Trade and Industry. He has been a member of numerous national and international panels and committees, including serving on several IARC panels. His research interests are: 1) chemical carcinogenesis, particularly of the urinary bladder; 2) cancer risk assessment; 3) low dose extrapolation and thresholds in carcinogenesis; and 4) the pathology of urinary bladder.

Goodman, Jay I., PhD

Dr. Jay I. Goodman is a professor of Pharmacology and Toxicology at Michigan State University, where he has served on the faculty since 1971. A Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences, Dr. Goodman is pursuing research focused on discerning the role(s) of altered DNA methylation as an epigenetic mechanism underlying the aberrant gene expression involved in carcinogenesis and other toxicities, and testing the hypothesis that susceptibility to carcinogenesis is related inversely to the capacity to maintain normal methylation patterns. He is a former president of the Society of Toxicology (SOT), and served as a member of the SOT’s Task Force to Improve the Scientific Basis for Risk Assessment. Dr. Goodman was an Associate Editor of numerous NIH, EPA, FDA, IARC and National Academy of Sciences study sections and scientific panels, and was a member of the National Toxicology Program’s Board of Scientific Counselors and Board of Scientific Counselors of the National Institute of Environmental Health Sciences (NIEHS). He is a member of the FEMA Expert Panel (Chairman, 2014-2016). He is on the editorial boards of several scientific journals in the areas of toxicology, pathology, and carcinogenesis, and is a reviewer for several other journals. He was president of the SOT Carcinogenesis Specialty Section and the SOT Central States Chapter of the Society of Toxicology, and recipient of the Society’s Arnold J. Lehman Award in 2001. He was named Distinguished Scientist in Cancer Research by the Japanese Foundation for Cancer Research in 2004, and received the George H. Scott Award from the Toxicology Forum and the Lifetime Achievement Award from the Association for Environmental Health and Science in 2012. He continues to be active in human surgical pathology. He has been actively involved with ILSI, RSI, and HESI since 1985, serving as a member of the HESI Board of Trustees since 2001 (Vice Chairman, 2004-6; Chairman, 2006-8) and the ILSI Board since 2007 (Vice Chairman, 2010-2012, Chairman, 2012-2015).
Guiney, Patrick D., PhD

Dr. Patrick Guiney is Director of Global Environmental Safety at S.C. Johnson & Son, Inc. He is responsible for conceiving and implementing global environmental toxicology research strategies and policies. Dr. Guiney has 37 years of broad-based experience in human health and ecological risk assessments. He has served internationally as Chair of several multidisciplinary scientific committees and advisory panels including the EPA’s Endocrine Disrupter Screening and Testing Standardization and Validation Ecotoxicology Advisory Panel. He is currently serving on the Health and Environmental Sciences Institute (HESI) Board of Trustees, as the Immediate President of the Society of Environmental Toxicology and Chemistry (SETAC - North America). He has served on the SNA Board of Directors for 7 years, on the SETAC World Council for 6 years, and is a Charter Member of SETAC. Dr. Guiney is a co-developer of S.C. Johnson’s award-winning Greenlist Program (an integrated computer-based approach for designing superior performing, environmentally responsible products from concept to market). He is also co-recipient of EPA’s 2006 Green Chemistry Award for work on Greenlist and co-recipient of the 2006 Presidential Award for Corporate Leadership-Environmental Sustainability (The Ron Brown Award). Dr. Guiney received his Ph.D. in Environmental Toxicology from the University of Wisconsin-Milwaukee. He has conducted research into the transport, bioaccumulation and fate of toxic substances at various levels of biological organization (molecular/biochemical to field studies). His current research interest include the application of molecular based models for screening and prioritizing potential endocrine disrupters, quantitative structure-activity relationships for investigating mechanisms of toxicity, ecological exposure assessment modeling for risk assessment, and alternative methods for predicting the bioaccumulation of persistent chemicals. He holds adjunct faculty appointments at the University of Wisconsin- Madison and Milwaukee, and has published over 45 peer-reviewed scientific papers in these areas of research.

Guzzie-Peck, Peggy J., PhD

Dr. Peggy J Guzie-Peck holds M.S. and Ph.D. degrees from the University of Pittsburgh in Toxicology/Human Genetics with an emphasis on Genetic Toxicology. She has broad experience in various aspects of toxicology and has been a diplomate of the American Board of Toxicology since 1987. Peggy joined Johnson & Johnson (Janssen Pharmaceuticals) in the Global Preclinical Development organization in 2007 and is currently the Global Head and investigative Safety Sciences in the Discovery Sciences Department with responsibilities for managing investigative de-risking activities, a key member of the Scientific Advisory Board, developing innovative technologies strategies, managing postdoctoral and consortia relationships, and interfacing with the Janssen Innovation Centers. Previous role in Janssen as the Global Head of Toxicology/Pathology and Laboratory Animal Medicine, with responsibilities for developing the strategy and delivering the operational goals at sites both in Raritan, NJ and Beerse, Belgium. Before joining Johnson & Johnson PCD, she has held several management-level positions at Pfizer, Inc. where she headed Genetic Toxicology in Groton, CT for over 10 years and led other disciplines including Safety Pharmacology, General Toxicology and Comparative Medicine as an Executive Director of Toxicology in Amboise, France. Prior to her career at Pfizer, she managed the Genetic Toxicology group at G.D. Searle and coordinated the outsourcing of worker safety and environmental impact testing. Throughout her career, she has served on several international expert work groups in Preclinical Safety, Genetic Toxicology, In Vitro Toxicology, Photosafety and Safety Pharmacology. She was a member of the PhRMA Preclinical Safety Leadership committee, chaired the PhRMA Genetic Toxicology and Phototoxicity Technical Groups, served on the council for the Environmental Mutagen Society, and chaired the Genetic Toxicology Association. She has also taught courses and lectured at several universities on various topics including Preclinical Safety Testing, Structural Activity Relationships, Carcinogenicity, Toxicoinformatics, and Genetic Toxicology.
Hanson, Laurie A., DVM, PhD, DABT

Dr. Hanson is currently Executive Director of the Study Management Group within Drug Safety Research & Development at Pfizer. This group is composed of the general toxicology study conduct group in Groton, CT as well as Global Resource Management and Global Strategic Outsourcing. She has held a number of scientific and management roles working in a wide variety of drug safety areas and supporting a number of therapeutic areas. She received a DVM in 1988 from Kansas State University and a PhD in Pharmacology from University of Kansas Medical Center in Kansas City in 1992. In 1995 she became a Diplomate of the American Board of Toxicology. In the past, Laurie served as Chair of the ILSI/HESI Nonclinical Cardiovascular Safety Studies Subcommittee on QT interval prolongation and has presented this work on behalf of HESI at several international meetings. In addition to being President of the HESI Board of Trustees, Laurie is currently a member of the Executive Committee, the Finance Committee, the Membership Development Committee.

Harpur, Ernie, BSc, PhD, ATS, FBTS

Following periods of doctoral and post-doctoral research in toxicology, Ernie spent 13 years in academia where his research interests centered on investigations of mechanisms of toxicity. Ernie subsequently worked for 21 years in Drug Safety Assessment in pharmaceutical industry based in Europe and the USA, for the last 9 years as Global Head of Scientific Affairs and Regulatory Standards. Since leaving industry in 2010, Ernie has held an honorary position in Toxicology within the Institute of Cellular Medicine at Newcastle University and engaged in various scientific advisory roles. He is a Registered Toxicologist and is active in several professional societies (past Scientific Secretary of the British Toxicology Society (BTS) and past President of EUROTX). He is a Fellow of the British Toxicology Society, a Fellow of the Academy of Toxicological Sciences and an honorary member of EUROTX. He has served on several expert committees, including the Safety, Efficacy and Adverse Reactions Sub-Committee of the UK Committee on Safety of Medicines. He has been active in a number of scientific consortia on both sides of the Atlantic serving recently as Chair of the HESI Renal Biomarkers Committee (now Scientific Advisor to this committee) and Vice Chair of the HESI Emerging Issues Committee and as a member of the Advisory Committee of the Predictive Safety Testing Consortium of the Critical Path Institute. Currently he is a member of the Board of Trustees, Executive Committee and Program Strategy and Stewardship Committee of HESI and chair of the Scientific Advisory Board of the UK public private partnership, Stem Cells for Safer Medicines. He is a member of the Executive Committee of the British Toxicology Society (recently elected Vice President). He has published more than 90 journal articles, reviews and book chapters and is a member of the editorial board of Toxicology Letters and Human & Experimental Toxicology.

Lau, Serrine S., PhD

Serrine S. Lau received her Ph.D. in Pharmacology from the University of Michigan. She was a Postdoctoral Fellow and Senior Staff Fellow with Dr. James Gillette and Dr. Michael Boyd at NHLBI and NCI, NIH, respectively. Dr. Lau is a Professor of Pharmacology and Toxicology, Director of the Southwest Environmental Health Sciences Center (http://swehsc.pharmacy.arizona.edu/) and Director of the Arizona Board of Reagents Center for Toxicology in the College of Pharmacy at the University of Arizona. Prior to her current position, Dr. Lau spent 17 years in the Division of Pharmacology and Toxicology at the University of Texas at Austin, and served as the Director of the NIEHS-supported Toxicology Training Program. Dr. Lau’s research focuses on three areas; (i) mechanisms of chemical-induced nephrotoxicity and nephrocarcinogenicity (ii) prostanoid and retinoid-mediated cytoprotection against ROS induced tissue injury, and (iii) proteomics approaches for the identification of chemical-induced protein post-translational modifications, and biomarker discovery for diseases including diabetes, asthma and cancer. Dr. Lau collaborates extensively with basic and clinical scientists, integrating the basic sciences with translational opportunities in environmental health sciences research. Dr. Lau has over 150 publications and 300 published abstracts. Dr. Lau’s research work has been funded by grants from the National Institutes of Health, National Science Foundation, the American Association of Colleges of Pharmacy, and the Pharmaceutical Manufacturers Association Foundation. Dr. Lau plays an active role in a number of professional organizations serving the field of toxicology and the environmental health sciences. She has served on many elected and appointed committees at SOT, ASPET, ISSX, NIH Study Section grant review panels and National Academy of Sciences. She completed her appointment as a member of the HESI Emerging Issues Steering Committee (June 2011), Chair of SOT Awards Committee (May 2012) and Chair of the SOT Board of Publications (May 2013). She
Lehman-McKeeman, Lois, PhD

Dr. Lois Lehman-McKeeman is Distinguished Research Fellow, Discovery Toxicology, at Bristol-Myers Squibb (BMS) in Princeton, NJ, where she has worked since 2001. Prior to joining BMS, she was employed in the Human and Environmental Safety Division of the Procter and Gamble. Dr. Lehman-McKeeman leads Discovery Toxicology and has active research interests broadly in biochemical mechanisms of toxicity. Her research also includes emphasis on the application and integration of metabolomic and transcriptomic technologies in mechanistic toxicology. She has published extensively in these fields. Dr Lehman-McKeeman received a BS degree in Toxicology from the University of the Sciences in Philadelphia and holds a Ph.D. in Toxicology from the University of Kansas Medical Center. She has been active professionally in the Society of Toxicology (SOT) serving on numerous SOT committees, and she has held elective office in the SOT as Councilor from 2000-2002 and the SOT Awards Committee (2008-2010). She was elected as Vice-President elect of the SOT in 2011, serving as President of the SOT in 2013-2014. In 2003, she was appointed Editor of Toxicological Sciences, a position she held through completion of the 2011 journal year. She has also served on a number of other editorial boards. Dr. Lehman-McKeeman has served on numerous national and international advisory committees for USEPA, NIH and IARC and the International Life Sciences Institute (ILSI). She was elected as a Fellow of the American Association for the Advancement of Science (AAAS) in 2008, and she is a fellow in the Academy of Toxicological Sciences. She was also the recipient of the Robert Scala Award in Toxicology for research excellence in an industrial laboratory (1994), the Society of Toxicology Achievement Award (2003) and the George H. Scott Award for scientific excellence from the Toxicology Forum (2006).

McQueen, Charlene A., PhD, ATS

Charlene A. McQueen assumed the position of Director of the Integrated Systems Toxicology Division in the US EPA National Health and Environmental Effects Research Laboratory in January 2011. Prior to that, she held positions at the Harrison School of Pharmacy, Auburn University (2007-2011) and the Department of Pharmacology and Toxicology at the University of Arizona (1990-2007). Dr. McQueen received a B.S. in Biology from Marywood College, Scranton, PA, M.S. in Pharmacology from New York University and Ph.D. in Human Genetics from the University of Michigan. Her research is in the areas of pharmacogenomics, toxicogenomics and chemical carcinogenesis. She is the Editor-in-Chief of the second edition of Comprehensive Toxicology and a member of the editorial board for References Modules in Biomedical Sciences. Dr. McQueen is an American Association for the Advancement of Science Fellow and a Fellow in the Academy of Toxicological Sciences (ATS). She was a member of the Board of Directors of ATS (2004-2009) serving as President in 2007-2008. Dr. McQueen received the Society of Toxicology (SOT) Public Communications Award (2003) and the SOT AstraZeneca Traveling Lectureship Award (2004). She has served on the SOT Program Committee, Education Committee, and chaired the K-12 Education Subcommittee. She has been a member of the SOT Council (1999-2001), the Council of the International Society for the Study of Xenobiotics (ISSX) (1994-1997) and the Executive Committee of the Drug Metabolism Division of the American Society of Pharmacology and Experimental Therapeutics (1997-2000). Dr. McQueen was on the Environmental Health Sciences Committee of the National Institute of Environmental Health Sciences, the Board of Scientific Councilors of the National Toxicology Program and the National Institutes of Health Cancer Etiology Study Section. Currently, Dr. McQueen is a member of the HESI Board of Trustees, the Board Secretary and a member of the ISSX Committee on Regulatory Affairs.

Moretto, Angelo, MD, PhD

Angelo Moretto is a professor of Occupational Medicine and Toxicology in the Department of Biomedical and Clinical Sciences at the University of Milan (Milan, Italy). Since 2006, he is also Director of the International Center for Pesticides and Health Risks Prevention (ICPS) at “Luigi Sacco” Hospital (Milan, Italy). He has been and currently is a member of many international and national committees for the risk assessment of exposure to chemical substances, in particular pesticides, and for the improvement, harmonization and innovation of risk assessment methods. Currently, he is a member of the following scientific organizations: Academy of Toxicological Sciences, International Commission on Occupational Health, International Neurotoxicology Association (Board member 2007-2008), Società Italiana di Medicina del Lavoro e Igiene Industriale (Board Member since 2011), Società Italiana di Tossicologia, and the Society of Toxicology. Prof. Moretto is a reviewer for over 15 journals, and has authored more than 70 papers in peer-review journal on toxicology, mainly neurotoxicology of pesticides, occupational toxicology, and toxicological risk assessment, and more than 20 review papers and book chapters.
Pastoor, Timothy P., PhD, DABT

Dr. Pastoor obtained his PhD in toxicology from the University of Michigan, is certified by the American Board of Toxicology (DABT), and is a long-standing, active member of the Society of Toxicology. Dr. Pastoor has over 30 years of international experience in fundamental toxicity testing, mode of action research, and human health risk assessment. For the majority of his career, including positions with DuPont, ICI, Zeneca, Novartis, and Syngenta, Dr. Pastoor led toxicology and risk assessment experts in the conduct of safety, health, and environmental studies to assess risk to humans and the environment. In his current role as Principal Scientist for Syngenta, Dr. Pastoor oversees toxicological research projects and product development and is a frequent lecturer on toxicology and risk assessment subjects. Dr. Pastoor has been involved in numerous ILSI-HESI projects. He helped organize the first peroxisome proliferation workshop, was a co-author of the Human Relevancy Framework, and co-chair of the Agricultural Chemical Safety Assessment committee. He is currently co-chairing the RISK21 project and is HESI’s vice-president.

Philbert, Martin A., PhD

Dr. Martin Philbert became dean of the University of Michigan School of Public Health on January 1, 2011, having previously served as senior associate dean for research at the school since 2004. He arrived at UM in 1995 from Rutgers’ Neurotoxicology Laboratories, where he was a research assistant professor. He has maintained a continuously federally funded portfolio of basic research activities throughout his career. Most recently his work has been funded by the National Institutes of Health, the Department of Air Force and the National Cancer Institute. At the national level, he is recognized for his expertise in neurotoxicology and experimental neuropathology. Dr. Philbert earned his PhD in Neurochemistry/Experimental Neuropathology in 1987 from London University (England). He is the author of numerous research publications in top peer-reviewed journals, and one book. In 2012, Dr. Philbert was elected to membership in the Institute of Medicine of the National Academy of Sciences and in 2013 he became a Fellow of the Royal Society of Chemistry.

Rickard, Robert W., PhD, DABT

Dr. Robert W. Rickard is a DuPont Distinguished Scientist for Health and Environmental Sciences in the DuPont SHE & Sustainable Growth Center. “DuPont Distinguished Scientist is the highest honor accorded by DuPont to a technical professional. The position is reserved for those scientists who have contributed significantly to DuPont’s advancement and global reputation in a scientific discipline.” In this role, Robert has oversight for DuPont’s global scientific competencies, policies and standards in health and environmental sciences. Robert has over 30 years of experience in various research and management positions at DuPont Haskell Global Center for Health and Environmental Sciences with emphasis on biochemical toxicology and chemical carcinogenesis and recent emphasis on the risk assessment of biopersistent chemicals in the environment. He received his Ph.D. in Toxicology from the University of Kentucky and a M.S. in Microbiology and a B.S. in Zoology from Clemson University. He has been certified as a Diplomat of the American Board of Toxicology since 1983 and he is a member of the Society of Toxicology. He currently serves on the Executive Committee and Board of Directors of The Hamner Institutes for Health Research, the Board of Trustees of the International Life Sciences Institute – Health and Environmental Science Institute (HESI) and the Board of Directors of the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). He also serves on numerous internal DuPont technical and strategic leadership teams.

Rowlands, J. Craig, PhD, DABT

Craig Rowlands is a Senior Scientist at The Dow Chemical Company’s Toxicology and Environmental Research and Consulting Organization (TERC). He advises Dow businesses on their toxicology and risk assessment needs with a goal towards sustainable chemistry. Dr. Rowlands has a leadership role in the TERC Science and Research activities, directing the TERC Strategic Research Program that focuses on refinement and development of current and future toxicology testing and risk assessment capabilities, and directs his own research program on environmental pollutants and applied research in chemical risk assessment. Dr. Rowlands is an adjunct professor at Michigan State University, Center for Integrative Toxicology and holds leadership positions in the Society for Toxicology, the American Chemistry Council and the International Life Sciences Institute, Health and Environmental Science Institute. Dr. Rowlands completed his Ph.D. in Toxicology at Texas A&M University and performed postdoctoral research in molecular endocrinology at the Karolinska Institute in Stockholm, Sweden. Prior to coming to Dow, Dr. Rowlands worked at the US FDA. Dr. Rowlands is a Diplomate of the American Board of Toxicology (DABT) and a Fellow of the American College of Nutrition (FACN).
Sambuiisho, Atushi, DVM, PhD

Dr. Atushi Sambuiisho is currently Science Advisor at the Medicinal Safety Research Laboratory (R&D Division) of Daiichi-Sankyo Co., Ltd. He joined Sankyo Co. Ltd. in 1992, and has held several positions within the company both before and after Sankyo merged with Daiichi to become Daiichi-Sankyo in 2007. Dr. Sambuiisho earned his PhD in 1988 from the College of Veterinary Medicine at the Ohio State University (Columbus, OH). He is a diplomate of the Japanese Society of Toxicology and the Japanese Teratology Society.

Smith, Lewis, PhD, FRCPath, FBTS

Professor Lewis Smith is currently working at the University of Leicester. He is professor of Biochemical Toxicology and contributes to various research initiatives. He was the initiating Director for three years of the Centre for Translational Therapeutics which is now led by Professor Andrew Tobin. Professor Smith began his career in 1971 at ICI Central Toxicology Laboratories and during which time completed his PhD studies under the supervision of Professor Norman Aldridge at the MRC Toxicology Unit in Carshalton. He left ICI in 1991 to become Director of the MRC Toxicology Unit which he relocated two years later from Carshalton to its current location within the University of Leicester. Professor Smith has published extensively on the mechanisms of toxicity of chemicals, pesticides and drugs and is particularly interested in the extrapolation of experimental data to man. In 1998 he moved as Director to Zeneca Central Toxicology Laboratory and assumed responsibility for Health and Environmental Safety. In 2002 he transferred to Syngenta Basel as Head of Development and then to other appointments in Research and Development. On retiring from Syngenta he returned to the University of Leicester. Professor Smith is a past President of the British Toxicology Society as well as having held different position on the Society’s committees. He is a past President of HESI and is currently a Trustee (Board member) of both HESI and ILSI. Professor Smith is also a Board member of IUTOX and is Chairman of the Toxicologists Recognition Task Force which is attempting to professionalize the qualifications and certification of Toxicologists on a global basis.

Stevens, James L., PhD

Dr. Stevens received his PhD in Pharmacology from the University of Minnesota in 1980 and was awarded a PRAT Fellowship from the National Institute of General Medical Sciences. He has held a number of positions including Senior Staff Fellow in the Bureau of Biologics, FDA (1983-1986), Senior Scientist (1986-1992) and then Executive Director (1992-1998) at the W. Alton Jones Cell Science Center, Lake Placid, NY, and Professor of Pathology at the University of Vermont (1998-2000). Dr. Stevens also served as a member of the Board of Directors for Upstate Biotechnology. He joined Lilly Research Laboratory in 2000 where he is a Distinguished Research Fellow. He was appointed a HESI Trustee in 2008 and to the NIGMS Science Advisory Council in 2009. He received the Achievement Award from the Society of Toxicology in 1994 and was elected a Fellow of the American Association for the Advancement of Sciences in 1996. His research interests focus on predictive and molecular/investigative toxicology and adverse drug reactions. He has published over 90 peer reviewed articles.

Tsuda, Hiroyuki. MD, PhD

Dr. Hiroyuki Tsuda received his M.D. from Nagoya City University in 1969 and his Ph.D. from the same University in 1975 under the supervision of Dr. Nobuyuki Ito. In 1975 he was a post-doctoral fellow in the Department of Pathology (Chairman, Dr. Emmanuel Farber) University of Toronto, Canada. In 1984, he was a Visiting Scientist, Division of Cytopathology (Chairman Dr. Peter Bannasch) German Cancer Research Center, Heidelberg, Germany. From 1989-1993, Dr. Tsuda was an Associate professor in the Second Department of Pathology, Fujita Health University School of Medicine. In 1993, he was promoted to the Chief of Experimental Pathology and Chemotherapy Division, National Cancer Center Research Institute, Tokyo. In 2003, he moved to Nagoya and assumed the position of head of the Department of Molecular Toxicology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. In 2011, he became Head of the Nanotoxicology Project, Nagoya City University. He has made considerable contributions for the WHO/International Agency for Research on Cancer since 1998 as a member of Fellowships Selection Committee, member of the Carcinogen Assessment Expert Group, and a Working Group Member of many publications including IARC Monographs on the Evaluation of Carcinogenicity to Humans and IARC Handbooks of Cancer Prevention and also several IARC Scientific Publication Series and many Monographs. He also served as an Advisory Group Member to Recommend Priorities for IARC Monographs since 2000 (4 terms, 20years). Recently he was selected as a member of the Advisory Group for IARC Monograph Volume 100 series, a review of the Group 1 Human Carcinogens. From 2003 he has been a member of the, Expert Committees of the Food Safety Commission of the Cabinet Office, Japan. He has been a member of the American Association for
Dr. Bennard van Ravenzwaay is senior vice president, experimental toxicology and ecology at BASF SE in Ludwigshafen, Germany. The experimental toxicology and ecology section is responsible for the conduct of all toxicological and ecotoxicological studies necessary for the notification and registration of chemicals, agrochemicals and cosmetic ingredients. Dr. van Ravenzwaay is a member of the following scientific organizations and societies: chairman of the scientific committee of the European Centre for Ecotoxicology and Toxicology, the European Crop Protection Association, the Program Committee for the German Society for Pharmacology and Toxicology, the German Society for Pharmacology and Toxicology, Eurotox, and the Society of Toxicology. He is a member of the editorial boards of both “Archives of Toxicology” and “Frontiers in Research.” He has authored or co-authored over 100 publications. He is a professor for toxicology at the University of Wageningen, Netherlands.
Kendall B. Wallace is a Professor and Associate Dean at the University of Minnesota Medical School on the Duluth campus. Dr. Wallace received his B.S. in Biochemistry from Michigan State University in 1975 and his Ph.D. in Physiology in 1979 from the same institution. He completed a two-year postdoctoral fellowship in the Toxicology Center at the University of Iowa before accepting an academic appointment first in Pharmacology and then Biochemistry and Molecular Biology at the University of Minnesota, Duluth. He has received a number of academic awards and recognitions, including “Basic Science Teacher of the Year” on 4 separate occasions. Dr. Wallace’s research interest is on the mitochondrion as a target for chemical-induced toxicity and the biochemical and molecular mechanisms that mediate such metabolic diseases. Dr. Wallace is a Diplomate of the American Board of Toxicology and served President of its Board of Directors in 2001-02. He is also Past-President of the Society of Toxicology and a Fellow of the Academy of Toxicological Sciences and president of its governing council. He has served on the executive committees for the Toxicology Division of ASPET (1992-98) and the IUTOX International Congress of Toxicology (1993-95; 2013-current). Dr. Wallace is co-Editor of the journal Toxicology and has served on scientific advisory panels to the NIEHS, NHLBI, the U.S. EPA and the U.S. FDA, including the Food Safety Advisory Committee. He is also a member of the Medical Expert Panel for the Vaccine Injury Compensation Program of the HHS. Dr. Wallace is a veteran with the ILSI organization as he has served as a scientific advisor to both the Risk Science Institute (1997-98) and the Health and Environmental Sciences Institute (1998-current).
Draft - 2014 HESI EXECUTIVE COMMITTEE AND OFFICERS*
*TO BE APPROVED BY HESI BOARD ON JUNE 2014

President (Term expires at close of 2015 Annual Meeting)  Dr. Laurie Hanson (private)
Vice President (Term expires at close of 2015 Annual Meeting)  Dr. Timothy Pastoor (private)
Past-Chair (Term expires at close of 2015 Annual Meeting)  Dr. Kendall Wallace (public)
Chair (Term expires at close of 2016 Annual Meeting)  Prof. Herman Autrup (public)
Vice-Chair (Term expires at close of 2016 Annual Meeting)  Dr. Ernie Harpur (public)
Secretary (Term expires at close of 2016 Annual Meeting)  Dr. Charlene McQueen (public)
Treasurer (Term expires at close of 2016 Annual Meeting)  Dr. Serrine Lau (public)
Member-at-Large (Term expires at close of 2015 Annual Meeting)  Dr. Brian Berridge (private)
Member-at-Large (Term expires at close of 2015 Annual Meeting)  Dr. Peggy Guzzie-Peck (private)
Member-at-Large (Term expires at close of 2015 Annual Meeting)  Dr. Martin Philbert (public)

2014 HESI REPRESENTATIVES TO THE ILSI BOARD OF TRUSTEES

Representative (Term expires at close of 2015 Annual Meeting)  Dr. Alan Boobis (public)**
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Ken Wallace (public)
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Scott Belanger (private)**
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Samuel Cohen (public)**
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Dennis Devlin (private)**
Representative (Term expires at close of 2015 Annual Meeting)  Dr. Lewis Smith (public)**

**ELECTED/RE-ELECTED BY ILSI AOM ON JANUARY 2014
NOMINATIONS TO THE
2014-2015 HESI EMERGING ISSUES COMMITTEE

Eight positions on the HESI Emerging Issues Committee (EIC) become vacant at the conclusion of
the 2014 Annual Meeting. Nominations were solicited for the following positions: a public sector
Vice Chair (from among existing EIC Science Advisors), four public sector Science Advisors, and
three private sector Science Advisors. At its February 2014 meeting, and in its capacity as
nominating committee, the EIC prioritized the list of candidates and recommends the following slate
of nominees:

Vice Chair:
    Dr. José Manautou, University of Connecticut (three-year term)

Public Sector Science Advisors:
    Dr. Suzanne Fitzpatrick, US FDA CFSAN (three-year term)
    Dr. Timothy Gant, CRCE, Public Health England (three-year term)
    Dr. George Gray, George Washington University (re-nomination, three-year term)
    Dr. Ronald Hines, US EPA NHEERL (three-year term)

Private Sector Science Advisors:
    Dr. Matthew Bogdanffy, Boehringer-Ingelheim (three-year term)
    Dr. Jon Cook, Pfizer, Inc. (three-year term)
    Dr. Andrew Glickman, Chevron Energy Technology Company (three-year term)
Manautou, José, PhD

Professor Manautou received a PhD in Pharmacology and Toxicology from Purdue University and a BS in Pharmacy from the University of Puerto Rico. Dr. Manautou's area of specialty is the mechanisms of target organ toxicity, with special emphasis on the liver, hepatic detoxification and disposition mechanisms, and hepatotoxicants and interference affecting susceptibility to chemical injury. He is a member of the editorial boards of Toxicology and Applied Pharmacology and Toxicological Sciences. As a faculty member at the University of Connecticut, he has a special interest in studying the mechanistic basis for protection against acetaminophen hepatotoxicity by repeated dosing with peroxisome proliferators. Another area of investigation deals with the role of transport proteins in the hepatobiliary disposition of xenobiotics and their metabolites. He also investigates the changes in expression of hepatic transporters in response to drug-induced liver injury and its functional consequences.
Bogdanffy, Matthew S., PhD, DABT, FATS

Dr. Bogdanffy spent 17 years with the DuPont Company in various roles including Research Manager and Director of Biochemical and Molecular Toxicology. He has been with Boehringer Ingelheim Pharmaceuticals in Ridgefield, Connecticut, since 2004 and is Director of Regulatory Toxicology. Dr. Bogdanffy has authored more than 80 research papers and book chapters in toxicology and risk assessment. He has served on the Editorial Board of several toxicology journals including Associate Editor for the journal *Toxicological Sciences*. He served as Councilor for the Society of Toxicology (2009–2011), and is an Adjunct Professor at the University of Connecticut, a Diplomate of the American Board of Toxicology, and a Fellow of the Academy of Toxicological Sciences since 2008. Dr. Bogdanffy received his PhD in Toxicology from Northeastern University, Boston, Massachusetts and was a postdoctoral fellow at the CIIT Centers for Health Research (now The Hamner Institutes for Health Sciences) in North Carolina.

Cook, John C., PhD, DABT

Jon C. Cook is Senior Director of Investigative Toxicology at Pfizer Inc. (1998-present). He is located in Groton, CT and leads the Investigative Toxicology group that de-risks findings observed in nonclinical studies. He has worked at Pfizer for 15 years on early and late-stage drug development teams. Jon worked with Searle colleagues to obtain approval for Celebrex and Valdecoxib. Jon later worked on the team to register Lasofoxifen and led de-risking efforts following complete response letters. More recently, he was a member of the team working on Lyrica de-risking of hemangiosarcoma to obtain the Generalized Anxiety Disorder indication. He currently leads a Drug Safety team of scientists to develop a Precision Medicine strategy for his line and is a member of the Compound Safety Prediction Leadership Team in Medicinal Chemistry. Prior to joining Pfizer Inc., he was a Senior Research Toxicologist at DuPont-Haskell Laboratory (1987-1998) and a Postdoctoral Fellow at Chemical Industry Institute of Toxicology (1985-1987). Dr. Cook received his B.S. in Physiology from the University of California, Davis, and his M.S. and Ph.D. degrees in Toxicology from North Carolina State University. He is a Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences. He served on the Editorial Boards of the *Journal of Toxicology and Environmental Health* (1988-1994), *Fundamental & Applied Toxicology* (1995-1998) and *Toxicological Sciences* (1998-2002). Dr. Cook received the Rutgers University Robert A. Scala Award in Toxicology in 1998. Dr. Cook has been active in the Society of Toxicology (SOT) throughout his career. He was elected to the “Presidential Chain” of the SOT serving as Vice President-Elect, Vice President, President, and Past President from 2009 – 2013 and to Council from 2002-2004. He has served on numerous SOT Committees including the Endowment Board (2007-2010, 2013-2015), Services Strategy Committee (2006-2007), and Continuing Education Committee (member, 1991-1996; Chair, 1993-1994). He has served as the Vice-President-Elect/Vice-President/President/Past-President of the SOT Carcinogenesis Specialty Section (2001-2005), Co-Editor of the Mid-Atlantic SOT Newsletter (1989-1993), SOT Council Liaison to Continuing Education Committee and Contemporary Concepts in Toxicology (CCT) Committee (2002-2004), SOT-SETAC Steering Committee for “Emerging Molecular and Computational Approaches for Cross-species Extrapolation” (2004-2005), and CCT Co-Chairperson of “Hemangiosarcoma In Rodents: Mode-Of-Action Evaluation And Human Relevance” (2008). Society memberships include SOT North Carolina.

Glickman, Andrew, PhD

Andy manages the Health and Product Stewardship Unit within Chevron Energy Technology Company. In this position, he oversees the toxicology, occupational hygiene, epidemiology and health risk assessment practices within Chevron Corporation. His personal expertise focuses on assessing the health and environmental impacts of oil and gas drilling and production operations. Andy has led efforts on environmental and regulatory issues associated with the risks of drilling and production discharges in Africa, Asia, North America, Latin America and the Caspian region. Andy chaired the American Petroleum Institute Production Effluent Toxicity and Synthetic Drilling Mud Toxicity Work Groups, and served on the Science Review Board of the MMS Gulf of Mexico Deepwater Environmental Monitoring Program. He recently chaired the Oil and Gas Producers Association (OGP) Offshore Environmental Monitoring Task Force and has been a leader in industry consortium programs on assessing offshore environmental impacts in Angola and Nigeria. In 2009, he was selected as a Society of Petroleum Engineers Distinguished Lecturer. His lecture described approaches to minimizing the environmental impacts of offshore drilling discharges. Andy received his bachelor’s degree in biology and chemistry from Antioch College, and his master’s and Ph.D. in pharmacology and toxicology from the Medical College of Wisconsin. Prior to joining Chevron 30 years ago, he was a research toxicologist at the University of California-Berkeley. Andy has been a diplomat of the American Board of Toxicology and is the author of over 30 papers on topics related to the toxicity and environmental impacts of chemicals, petroleum products and effluents.
Fitzpatrick, Suzanne C., PhD, DABT  
Dr. Suzanne Fitzpatrick is Senior Advisor for Toxicology at the US Food and Drug Administration Center for Food Safety & Applied Nutrition. As the Human Protection Administrator for the FDA Institutional Review Board, she drafted the Standard Operating Procedures for the FDA IRB and oversees its daily activities. Dr. Fitzpatrick is a board certified toxicologist. She is the past president of the American College of Toxicology and also a past member of its board of councilors. Dr. Fitzpatrick is President of the In Vitro and Alternative Methods Specialty Section of the Society of Toxicology, Vice President-Elect of the SOT Regulatory and Safety Evaluation Specialty Section of SOT, and a past president of the SOT National Capital Area Chapter. She is also an adjunct professor at Johns Hopkins University, Zanvyl Krieger School of Arts and Science. Dr. Fitzpatrick received her BA from the University of California at San Diego and her PhD from Georgetown University.

Gant, Timothy, PhD  
Dr. Timothy Gant is Head of the Toxicology Department, Centre for Radiation, Environmental and Chemical Hazards, Public Health England (an executive agency of the Department of Health in the United Kingdom). Formerly, Dr. Gant was a Medical Research Council (Toxicology Unit) group leader (1993-2011) and visiting fellow of the National Institutes of Health in the United States. He is a European Registered Toxicologist with experience in drugs, chemicals, genomics, genetics, bioinformatics, high throughput sequencing and mechanisms of toxicology. Dr. Gant is Visiting Professor of the Faculty of Health and Medical Sciences, University of Surrey; Honorary Senior Research Fellow of Imperial College London; and Honorary Reader Department of Genetics, University of Leicester. Dr. Gant's current research focus includes both chemicals and drugs, with an emphasis on public health. His specialties include mechanisms of chemical and drug toxicity, cancer drug resistance mechanisms, genomics, and bioinformatics. Dr. Gant received his PhD in Pharmacology from the University of London.

Gray, George, PhD  
George Gray is a professor in the Department of Environmental and Occupational Health and Director of the Center for Risk Science and Public Health at George Washington University in Washington, DC. He received his BS in Biology in 1985 from the University of Michigan, his MS in Toxicology in 1988 from the University of Rochester School of Medicine and Dentistry, and his PhD in 1989 from the University of Rochester School of Medicine and Dentistry. Prior to joining GWU’s School of Public Health and Health Services (SPHHS) in 2010, Professor Gray served as assistant administrator for the EPA's Office of Research and Development and as the agency science advisor, promoting scientific excellence in EPA research, advocating for the continuing evolution of the agency's approach to analysis, and encouraging programs that provide academic research to support EPA's mission. His areas of focus included nanotechnology, ecosystem research, the influence of toxicology advances on testing and risk assessment, and sustainability. From 2001 to 2005, Professor Gray was executive director of the Harvard Center for Risk Analysis, and a member of the faculty at the Harvard School of Public Health. In addition to teaching, he applied the tools of risk analysis to public health problems ranging from mad cow disease to pesticides in food to the risks and benefits of fish consumption. Dr. Gray's primary research interests center around risk characterization, risk communication, and risk policy. He has
Hines, Ronald N., PhD

Dr. Ronald Hines is Associate Director for Health with the National Health and Environmental Effects Research Laboratory (NHEERL) at the US Environmental Protection Agency in Research Triangle Park, NC. Previously, Dr. Hines was Professor of Pediatrics and Pharmacology/Toxicology at the Medical College of Wisconsin and Co-Chief, Section of Clinical Pharmacology, Pharmacogenetics and Teratology; Associate Director, Children’s Research Institute, Children’s Hospital and Health Systems; Deputy Director of the NIEHS Children’s Environmental Health Sciences Core Center, a joint activity between the University of Wisconsin Milwaukee and the Medical College of Wisconsin; and Co-Leader of the Molecular Carcinogenesis and Chemoprevention Program, Medical College of Wisconsin Cancer Center. He received his Ph.D. in Biochemistry from the University of Texas Southwestern Medical School in 1980 and completed postdoctoral training in Biochemistry and Molecular Biology at the University of Vermont in 1983. Earlier in his career, Dr. Hines was a member of the faculties of the Eppley Cancer Research Institute and the Department of Biochemistry, University of Nebraska Medical Center and the College of Medicine, Department of Pharmacology, Wayne State University. At Wayne State University, he also had leadership roles in the NCI Karmanos Cancer Center and the NIEHS Environmental Health Sciences Core Center. Dr. Hines currently serves as an Associate Editor for both the *Journal of Pharmacology and Experimental Therapeutics and Chemico-Biological Interactions*. He is a member of the *Drug Metabolism and Disposition* editorial board. He has served on numerous national review panels and advisory boards and was chair of the NIEHS Environmental Health Sciences Review Committee and a member of the FDA/NCTR Scientific Advisory Board. Dr. Hines is an active member of the Society of Toxicology and the American Society for Pharmacology and Experimental Therapeutics and has served in leadership roles for both organizations. He also is a Fellow of the Academy of Toxicological Sciences and was a member of the HESI Board of Trustees. Dr. Hines’ research interests are focused on the regulation of genes encoding enzymes involved in drug and toxicant metabolism and in particular, underlying mechanisms responsible for temporal- and tissue-specific expression patterns. A second major focus deals with mechanisms controlling interindividual differences in gene expression and how this variability impacts response, susceptibility and risk for adverse events.
HESI EMERGING ISSUES COMMITTEE

ROSTER
(June 2013 – June 2014)

LEADERSHIP (one-year term in each leadership position)
Chair: Hal Zenick, PhD, US Environmental Protection Agency (term expires June 2015)
Vice Chair: Ruth A. Roberts, PhD, FBTS, ATS, ERT, FRCPath, AstraZeneca R&D (term expires June 2016)
Past Chair: Stephen J. Newsholme, BSc, BVetMed, MMedVet (Path), Diplomate ACVP, MRCVS, GlaxoSmithKline (term expires June 2014)

SCIENCE ADVISORS (public sector) (three-year terms)
Darlene Dixon, DVM, PhD, DACVP, National Institute of Environmental Health Sciences (term expires June 2014)
Jesse L. Goodman, MD, MPH, Georgetown University Medical Center (term expires June 2014)
George Gray, PhD, George Washington University (term expires June 2014)
Toshihisa Ishikawa, PhD, RIKEN Yokohama Institute (term expires June 2015)
James E. Klaunig, PhD, ATS, Indiana University (renewed; term expires June 2016)
José E. Manautou, PhD, ATS, University of Connecticut (term expires June 2015)
Derek C.G. Muir, PhD, Environment Canada (renewed; term expires June 2016)
Flavio A.D. Zambrone, MD, PhD, University of Taubaté / Planitox (term expires June 2016)

SCIENCE ADVISORS (private sector) (three-year terms)
Cynthia A. Afshari, PhD, DABT, Amgen Inc. (term expires June 2014)
Robert A. Barter, PhD, ExxonMobil Biomedical Sciences (term expires June 2015)
Ann M. Blacker, PhD, DABT, Bayer CropScience (term expires June 2016)
Daniel A. Goldstein, MD, Monsanto Company (term expires June 2015)
Michael Graziano, PhD, DABT, Bristol-Myers Squibb (term expires June 2016)
Patrick D. Guiney, PhD, SC Johnson & Son, Inc. (term expires June 2014)
Kathleen A. Shelton, PhD, DuPont Haskell Global Centers for Health and Environmental Sciences (term expires June 2016)

EX OFFICIO MEMBERS (Leadership, HESI Board Program Strategy and Stewardship Committee)
Herman N. Autrup, PhD, University of Aarhus
Timothy Pastoor, PhD, DABT, Syngenta Ltd.
HESI EMERGING ISSUES COMMITTEE

PROPOSED ROSTER
(June 2014 – June 2015)

LEADERSHIP (one-year term in each leadership position)
Chair: Ruth A. Roberts, PhD, FBTS, ATS, ERT, FRCPath, AstraZeneca R&D (term expires June 2016)
Vice Chair: José E. Manautou, PhD, ATS, University of Connecticut (term expires June 2017)
Past Chair: Hal Zenick, PhD, US Environmental Protection Agency (term expires June 2015)

SCIENCE ADVISORS (public sector) (three-year terms)
Suzanne C. Fitzpatrick, PhD, DABT, US Food and Drug Administration (term expires June 2017)
Timothy Gant, PhD, CRCE, Public Health England (term expires June 2017)
George Gray, PhD, George Washington University (term expires June 2017)
Ronald N. Hines, PhD, US Environmental Protection Agency (term expires June 2017)
Toshihisa Ishikawa, PhD, NPO Personalized Medicine & Healthcare (term expires June 2015)
James E. Klaunig, PhD, ATS, Indiana University (term expires June 2016)
Derek C.G. Muir, PhD, Environment Canada (term expires June 2016)
Flavio A.D. Zambrone, MD, PhD, University of Taubaté / Planitox (term expires June 2016)

SCIENCE ADVISORS (private sector) (three-year terms)
Robert A. Barter, PhD, ExxonMobil Biomedical Sciences (term expires June 2015)
Ann M. Blacker, PhD, DABT, Bayer CropScience (term expires June 2016)
Matthew S. Bogdanify, PhD, DABT, ATS, Boehringer-Ingelheim (term expires June 2017)
Jon C. Cook, PhD, DABT, Pfizer, Inc. (term expires June 2017)
Andrew Glickman, PhD, Chevron Energy Technology Company (term expires June 2017)
Daniel A. Goldstein, MD, Monsanto Company (term expires June 2015)
Michael Graziano, PhD, DABT, Bristol-Myers Squibb (term expires June 2016)
Kathleen A. Shelton, PhD, DuPont Haskell Global Centers for Health and Environmental Sciences (term expires June 2016)

EX OFFICIO MEMBERS
(2014-2015 Leadership, HESI Board Program Strategy and Stewardship Committee)
Timothy Pastoor, PhD, DABT, Syngenta Ltd.
Ernie S. Harpur, BSc, PhD, ATS, FBTS, Newcastle University

*Highlighted names indicate proposed members.